Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Perspective Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-32.4-26.0
Net income-32.4-26.0
EPS (diluted, $ a share)$-0.27$-0.35

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: CATX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Perspective Therapeutics, Inc.: key numbers

Share price
$0.9238Close, Nov 16
Market cap
$112M
Shares outstanding
120.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Perspective Therapeutics, Inc.

All →
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Frank Morich Buys $14K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9364 a share, worth $14K in total on Nov 16, 2026. Shares held after the trade: 30,000 (+100.0%).

Value
$14K
Shares
15,000
Price
$0.9364
Role
Director
Holding change
+100.0%
Trade date
Nov 16, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Robert F. Williamson III Buys $15.6K of Stock

Robert F. Williamson III, Director, bought 18,609 shares of Perspective Therapeutics, Inc. at $0.84 a share, worth $15.6K in total on Nov 12, 2026. Shares held after the trade: 28,473 (+188.7%).

Value
$15.6K
Shares
18,609
Price
$0.8400
Role
Director
Holding change
+188.7%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Frank Morich Buys $15K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.

Value
$15K
Shares
15,000
Price
$0.9971
Role
Director
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Lori A. Woods Buys $20K of Stock

Lori A. Woods, Director, bought 23,750 shares of Perspective Therapeutics, Inc. at $0.8438 a share, worth $20K in total on Nov 12, 2026. Shares held after the trade: 28,557 (+494.1%).

Value
$20K
Shares
23,750
Price
$0.8438
Role
Director
Holding change
+494.1%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics CMO Markus Puhlmann Buys $29.6K of Stock

Markus Puhlmann, CMO, bought 35,000 shares of Perspective Therapeutics, Inc. at $0.8447 a share, worth $29.6K in total on Nov 12, 2026. Shares held after the trade: 178,542 (+24.4%).

Value
$29.6K
Shares
35,000
Price
$0.8447
Role
CMO
Holding change
+24.4%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics CEO Johan M. Spoor Buys $37.9K of Stock

Johan M. Spoor, CEO, bought 47,000 shares of Perspective Therapeutics, Inc. at $0.8073 a share, worth $37.9K in total on Nov 11, 2026. Shares held after the trade: 106,383 (+79.1%).

Value
$37.9K
Shares
47,000
Price
$0.8073
Role
CEO
Holding change
+79.1%
Trade date
Nov 11, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.